NeoGenomics Laboratories, Inc. (NEO)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$17.38-0.46%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
Intact: The reason to own it still holds.
NeoGenomics grows revenue about 10% yearly, reaching $800 million in 2026. It cuts net loss by 34% and raises adjusted EBITDA 27%. New cancer tests like RaDaR ST MRD support long-term growth. Management shows steady progress on key goals.
The company still loses money and profit margins remain thin. Growth could slow below 10%. New products may not gain enough market share to offset costs. High valuation risks disappointment if earnings do not improve.
The market expects about 12% revenue growth next year, roughly in line with guidance. Our fair value near $9 matches consensus, reflecting typical peer valuation. We see risk if profitability improvements stall or growth slows.
Breaks if: new product launches fail to gain market traction or coverage
Develop and commercialize new advanced cancer diagnostic tests including RaDaR ST and PanTracer products to expand market presence.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with a focus on improving revenue and profitability. The current thesis state is intact, supported by recent financial performance that remains strong relative to its industry.
The market appears to price in a fragile situation, with an expensive valuation compared to peers. There is an expectations gap, suggesting that investors may not fully account for the potential volatility in NEO's performance.
Management is focused on enhancing revenue growth and improving operating income, with recent results showing progress in these areas. However, the company remains loss-making, and risks from the broader economic environment could impact its trajectory.
The future performance of NEO hinges on its ability to maintain revenue growth and successfully launch new products. Additionally, broader sector performance and economic indicators will play a crucial role in shaping investor sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats impacting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 4 quarters. Management highlights launching RaDaR ST MRD assay and PanTracer products with reimbursement progress. While revenue contribution from MRD is modest in 2026, these product launches represent strategic innovation. The trajectory shows ongoing development and market preparation.
“Submitted new RaDaR ST evidence to MolDx supporting Medicare reimbursement for a new indication.”
“Launched RaDaR ST, a circulating tumor DNA assay for detecting molecular residual disease (MRD).”
“Successfully resolved RaDaR ST patent litigation and preparing for clinical launch.”
Breaks if: net loss reduction stalls or reverses; adjusted EBITDA fails to grow
Breaks if: annual revenue falls below $727 million (2025 level) in FY26
Continue driving double-digit revenue growth through clinical services expansion and advanced testing modalities like NGS.
Stated as a priority in 4 of last 4 quarters. Revenue grew 11% year-over-year in 2026-Q2 to $202 million, with NGS revenue growth of 26%. Full year 2025 revenue increased 10% to $727 million. Management consistently emphasizes revenue growth driven by clinical services and advanced testing, and the financials show delivering growth.
“Revenue growth of 11% year-over-year exceeded our outlook, with NGS revenue growth of 26%.”
“Consolidated revenue increased 11% to a first quarter record $187 million, driven by Clinical revenue growth of 14%.”
“Fourth quarter consolidated revenue increased 11% to $190 million; Full year consolidated revenue increased 10%.”
“Full year 2025 revenue increased 10% over 2024, reflecting increased test volumes and mix shift toward higher value tests.”
Over the next 1 to 3 years, NEO's prospects will depend on its execution of strategic priorities amid a mixed economic backdrop. Not investment advice.